Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Other anti-copper agents
Pharmacodynamic studies were conducted in Wilson’s disease patients on the combination of Wilzin
(50 mg three times daily) with ascorbic acid (1 g once daily), penicillamine (250 mg four times daily),
and trientine (250 mg four times daily). They showed no significant overall effect on copper balance
although mild interaction of zinc with chelators (penicillamine and trientine) could be detected with
decreased faecal but increased urinary copper excretion as compared with zinc alone. This is probably
due to some extent of complexion of zinc by the chelator, thus reducing the effect of both active
substances.
When switching a patient on chelating treatment to Wilzin for maintenance therapy, the chelating
treatment should be maintained and co-administered for 2 to 3 weeks since this is the time it takes for
the zinc treatment to induce maximum metallothionein induction and full blockade of copper
absorption. The administration of the chelating treatment and Wilzin should be separated by at least
1 hour.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Other anti-copper agents
Pharmacodynamic studies were conducted in Wilson’s disease patients on the combination of Wilzin
(50 mg three times daily) with ascorbic acid (1 g once daily), penicillamine (250 mg four times daily),
and trientine (250 mg four times daily). They showed no significant overall effect on copper balance
although mild interaction of zinc with chelators (penicillamine and trientine) could be detected with
decreased faecal but increased urinary copper excretion as compared with zinc alone. This is probably
due to some extent of complexion of zinc by the chelator, thus reducing the effect of both active
substances.
When switching a patient on chelating treatment to Wilzin for maintenance therapy, the chelating
treatment should be maintained and co-administered for 2 to 3 weeks since this is the time it takes for
the zinc treatment to induce maximum metallothionein induction and full blockade of copper
absorption. The administration of the chelating treatment and Wilzin should be separated by at least
1 hour.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ulipristal acetate is metabolised by CYP3A4 in vitro.
- CYP3A4 inducers
In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer
such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and
decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold
decrease of ulipristal acetate exposure. Concomitant use of ellaOne with CYP3A4 inducers (e.g.
barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine,
oxcarbazepine, herbal medicines containing Hypericum perforatum (St. John’s wort),
rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma
concentrations of ulipristal acetate and may result in a decreased efficacy of ellaOne. For
women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended
(see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device
(Cu-IUD)) should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Ulipristal acetate is metabolised by CYP3A4 in vitro.
- CYP3A4 inducers
In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer
such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and
decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold
decrease of ulipristal acetate exposure. Concomitant use of ellaOne with CYP3A4 inducers (e.g.
barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine,
oxcarbazepine, herbal medicines containing Hypericum perforatum (St. John’s wort),
rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma
concentrations of ulipristal acetate and may result in a decreased efficacy of ellaOne. For
women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended
(see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device
(Cu-IUD)) should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 87464f734672865ea9df447f4532cd92447404847005d1bb51fb5ed63267d21a · Zeichen 69–1159 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.